Data provide first human validation of cardiac energetics modulation as a therapeutic target in cardiometabolic heart disease, including heart ...

Background Ebstein’s anomaly (EA) exhibits significant anatomical and clinical heterogeneity, warranting a systematic ...

The U.S. Food and Drug Administration has approved Myqorzo (aficamten) for the treatment of adults with symptomatic ...

Discover why Edgewise Therapeutics, Inc. is rated Buy amid strong trial data, unique HCM treatment, and major 2026 catalysts. Click for this EWTX update.

Cytokinetics has announced that the US Food and Drug Administration (FDA) has approved MYQORZO (aficamten) tablets in 5mg, 10mg, 15mg, and 20mg doses for adults with symptomatic obstructive ...

aBritish Heart Foundation Centre of Research Excellence, School of Cardiovascular Medicine, Faculty of Life Science, King's College London, London, UK Heart failure is a complex clinical syndrome ...

Background: Substantial evidence supports the utility of cardiac magnetic resonance feature tracking (CMR-FT) in evaluating subclinical cardiac dysfunction. This study investigated the clinical value ...

Samsung is working on ways to detect Left Ventricular Systolic Dysfunction (LVSD) using the Galaxy Watch. It has also conducted trials and received approval from South Korea’s Ministry of Food and ...

Panel A shows a cross-section of a normal heart (top) and an endomyocardial biopsy sample from a normal heart (bottom; with hematoxylin and eosin staining) that shows normal histologic characteristics ...

LBBB is linked to electrical abnormalities, causing inefficient heart pumping, dilation, and systolic dysfunction. The study found LBBB associated with increased heart failure risk, surpassing other ...